Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

323 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Després JP, et al. N Engl J Med. 2005 Nov 17;353(20):2121-34. doi: 10.1056/NEJMoa044537. N Engl J Med. 2005. PMID: 16291982 Clinical Trial.
METHODS: We randomly assigned 1036 overweight or obese patients (body-mass index [the weight in kilograms divided by the square of the height in meters], 27 to 40) with untreated dyslipidemia (triglyceride levels >1.69 to 7.90 mmol per liter, or a ratio of cholesterol t …
METHODS: We randomly assigned 1036 overweight or obese patients (body-mass index [the weight in kilograms divided by the square of the heigh …
[Nutrition-obesity. Rimonabant and cardiovascular risk factors].
Vincent M, Golay A. Vincent M, et al. Rev Med Suisse. 2009 Jan 7;5(185):49-52. Rev Med Suisse. 2009. PMID: 19216325 French.
Rimonabant, a CB1-blocker brings novel perspective to manage several cardiovascular risk factors. Unfortunately, Rimonabant has been withdrawn from the market. ...
Rimonabant, a CB1-blocker brings novel perspective to manage several cardiovascular risk factors. Unfortunately, Rimonabant has been …
[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
Scheen AJ, Van Gaal LG, Després JP, Pi-Sunyer X, Golay A, Hanotin C. Scheen AJ, et al. Rev Med Suisse. 2006 Aug 23;2(76):1916-23. Rev Med Suisse. 2006. PMID: 16972542 Review. French.
RIO (Rimonabant In Obesity and related disorders) is a large phase 3 programme (>6600 patients) evaluating the efficacy and safety of rimonabant (5 or 20 mg/day), a CBI receptor antagonist of endocannabinoid system, in obese or overweight patients with or without …
RIO (Rimonabant In Obesity and related disorders) is a large phase 3 programme (>6600 patients) evaluating the efficacy and safety …
[New obesity and metabolic syndrome treatment: rimonabant].
Makoundou V, Golay A. Makoundou V, et al. Rev Med Suisse. 2006 Jan 4;2(47):41-5. Rev Med Suisse. 2006. PMID: 16465944 Review. French.
Rimonabant is a new pharmacological therapy and very interesting for tackling obesity and metabolic syndrome....
Rimonabant is a new pharmacological therapy and very interesting for tackling obesity and metabolic syndrome....
Efficacy of rimonabant in obese patients with binge eating disorder.
Pataky Z, Gasteyger C, Ziegler O, Rissanen A, Hanotin C, Golay A. Pataky Z, et al. Exp Clin Endocrinol Diabetes. 2013 Jan;121(1):20-6. doi: 10.1055/s-0032-1329957. Epub 2012 Nov 12. Exp Clin Endocrinol Diabetes. 2013. PMID: 23147209 Clinical Trial.
In obesity, a dysregulation of the endocannabinoid system has been shown. The endocannabinoid receptor blockage by rimonabant demonstrated interesting metabolic effects. ...The rimonabant group showed a greater reduction on the binge eating scale total score (mean±S …
In obesity, a dysregulation of the endocannabinoid system has been shown. The endocannabinoid receptor blockage by rimonabant demonst …
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. Sjöström L, et al. Lancet. 1998 Jul 18;352(9123):167-72. doi: 10.1016/s0140-6736(97)11509-4. Lancet. 1998. PMID: 9683204 Clinical Trial.
BACKGROUND: We undertook a randomised controlled trial to assess the efficacy and tolerability of orlistat, a gastrointestinal lipase inhibitor, in promoting weight loss and preventing weight regain in obese patients over a 2-year period. ...In a secon …
BACKGROUND: We undertook a randomised controlled trial to assess the efficacy and tolerability of orlistat, a gastrointestinal …
Blunted glucose-induced thermogenesis in 'overweight' patients: a factor contributing to relapse of obesity.
Golay A, Schutz Y, Felber JP, Jallut D, Jéquier E. Golay A, et al. Int J Obes. 1989;13(6):767-75. Int J Obes. 1989. PMID: 2621050
In the formerly overweight patients, the combined effect of a decreased basal energy expenditure and an attenuation of glucose induced thermogenesis resulted in a postprandial energy expenditure which was markedly lower than in the overweight state (P less than 0.00 …
In the formerly overweight patients, the combined effect of a decreased basal energy expenditure and an attenuation of glucose induce …
From metabolic normality to cardiometabolic risk factors in subjects with obesity.
Bobbioni-Harsch E, Pataky Z, Makoundou V, Laville M, Disse E, Anderwald C, Konrad T, Golay A; RISC Investigators. Bobbioni-Harsch E, et al. Obesity (Silver Spring). 2012 Oct;20(10):2063-9. doi: 10.1038/oby.2012.69. Epub 2012 Mar 16. Obesity (Silver Spring). 2012. PMID: 22421925 Clinical Trial.
Ow/ob subjects who, at 3 years follow-up, remained metabolically normal, showed a less favourable cardiometabolic profile, when compared to nbw counterparts. ...In conclusion, metabolically normal obese subjects show a higher incidence of cardiometabolic risk factor …
Ow/ob subjects who, at 3 years follow-up, remained metabolically normal, showed a less favourable cardiometabolic profile, when compa …
[Cardio-metabolic profile is influenced by modest modifications of body weight].
Pataky Z, Bobbioni-Harsch E, Golay A. Pataky Z, et al. Rev Med Suisse. 2012 Mar 28;8(334):670-2. Rev Med Suisse. 2012. PMID: 22512131 French.
There is a quasi linear relationship between BMI and number of MS components: an increase in BMI is associated with increasing number of cardio-metabolic alterations. ...On the other hand, a modest weight loss is associated with decrease of MS components number and …
There is a quasi linear relationship between BMI and number of MS components: an increase in BMI is associated with increasing number …
323 results
Jump to page
Feedback